知ってるつもりの　内科レジデントの常識非常識　第2版

第1章 48の超常識

P.7 掲載の参考文献

Shekelle PG, Ortiz E, et al:Validity of the Agency for Healthcare Research and Quality clinical practice guidelines:how quickly do guidelines become outdated? JAMA 286 (12):1461-1467, 2001

PubMed

第2章 28の非常識

P.29 掲載の参考文献

Black HR, Curb JD, et al:Systolic hypertension in the elderly program. Hypertension 17 (suppl 2):1-171, 1991

 

P.38 掲載の参考文献

太田大介:隠れたうつの初発症状. 治療 87:461-466, 2005

Medical*Online

P.41 掲載の参考文献

1) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91 (1):66-72, 1999

 

2) Gridelli C, et al:MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer:the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (5):362-372, 2003

 

特定非営利活動法人日本緩和医療学会 「緩和医療の定義」 http://www.jspm.ne.jp/

 

がん情報サービス 「緩和ケアとは」 http://ganjoho.ncc.go.jp/public/support/relaxation/about_care.html

 

第3章 468の常識

P.49 掲載の参考文献

Nohria A, Tsarg SW, et al:Clinical assessment identifies hemodynamic profiles that predict outcome in patients admitted with heart failure. J Am Coll Cardial 41:1797-1804, 2003

 

P.59 掲載の参考文献

Noninvasive ventilation in acute cardiogenic pulmonary edema:systemic review and meta-analysis. JAMA 294:3124-3130, 2005

 

P.66 掲載の参考文献

Weis NS:The United States Health Examination Survey of Adults. N Engl J Med 287:631, 1973

 

P.67 掲載の参考文献

Mancia G, et al:Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9:209-215, 1987

PubMed

P.70 掲載の参考文献

笠貫 宏:非持続性心室頻拍. medicina 32:982, 1995

 

杉本恒明, 他:不整脈 (頻脈性) 薬物治療ガイドライン. 日本医事新報, No. 3629:11, 1993より改変

 

P.125 掲載の参考文献

1) Schiller JH, et al:Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002

PubMed

1) Marino P, et al:Chemotherapy vs supportive care in advanced non small cell lung cancer. Result of a meta-analysis of the literature. Chest 106:861-865, 1994

PubMed

2) Non-small Cell Lung Cancer Collaborative Group:Chemotherapy in non-small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995

 

2) Ohe Y, et al:Randamized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:four-arm cooperative study in Japan. Ann Oncol 18:317-323, 2007

 

3) Spiro SG, et al:Chemotherapy versus supportive care in advanced non-small cell lung cancer:improved survival without detriment to quality of life. Thorax 59:828-836, 2004

PubMed

P.126 掲載の参考文献

1) The Elderly Lung Cancer Vinorelbine Italian Study Group:Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66-72,1999

 

1) Takada M, et al:Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer:results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3045-3047, 2002

 

2) Kudoh S, et al:Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer:results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657-3663, 2006

PubMed

2) Noda K, et al:Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002

PubMed

3) Tsuchiya R, et al:Phase III trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-III a small cell lung cancer:the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 129:977-983,2005

 

P.127 掲載の参考文献

1) Slotman B, et al:Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664-672, 2007

PubMed

2) Auperin A, et al:Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484 1999

 

P.266 掲載の参考文献

日本心身医学会教育研修委員会:心身医学の新しい診療指針. 心身医 31:537-576, 1991

 

P.269 掲載の参考文献

The American Psychiatric Association:Quick Reference to the Diagnostic Criteria from DSM4th. 1994 (高橋三郎, 大野 裕, 染谷俊幸訳:DSM4th 精神疾患の分類と診断の手引き. 医学書院, 1996)

 

P.271 掲載の参考文献

太田大介:レジデントに贈る心療内科の思考プロセス. 南山堂, 2007

 

P.273 掲載の参考文献

Beauchamp T, Childress J:Principles of Biomedical Ethics, 5th Edition, Oxford University Press, Oxford, 2001

 

P.279 掲載の参考文献

Sackett DL, et al:Evidence-based medicine; How to practice and teach EBM. Churchill Livingstone, 2000

 

P.280 掲載の参考文献

Billings, et al:The Clinical Encounter:A guide to the medical interview and case presentation, Year Book Medical Publishers, 1999

 

P.282 掲載の参考文献

Differential Diagnosis in Primary Care. R. Douglas Collins (4th edition), Lippincott Williams & Wilkins, 2007

 

P.291 掲載の参考文献

CDC 2006 STD Treatment guidelines www.cdc.gov/std/treatment

PubMed

P.298 掲載の参考文献

田中まゆみ:研修医のためのリスクマネジメントの鉄則. 医学書院, 印刷中

 

P.311 掲載の参考文献

Baile WF,et al:SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer.Oncologist 5 (4):302-311,2000

 

P.312 掲載の参考文献

1) Therasse P, et al:New guidelines to evaluate to response to treatment in solid tumors. J Natl Cancer Inst 92:179-181, 2000

 

2) 固形がんの治療効果判定のための新ガイドライン(RECISTガイドライン)-日本語訳JCOG版-(日本臨床腫瘍研究グループ http://www.jcog.jp/SHIRYOU/recist.htm)

 

Oken MM, et al:Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982

PubMed

P.313 掲載の参考文献

抗悪性腫瘍薬の臨床評価方法に関するガイドライン http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/171101-b.pdf

 

P.314 掲載の参考文献

コンセンサス癌治療, 抗癌剤の副作用; 予期して臨むことの大切さ http://www.cancertherapy.jp/anticancer/2006_autumn/index.html

 

NCCN http://www.nccn.org/

 

日本語版 http://www7a.biglobe.ne.jp/~jccnb/nccn_gl/gl12fev.pdf

 

IDSAガイドライン http://www.idsociety.org/

 

P.316 掲載の参考文献

1) Hortobagyi GN, et al:Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335 (24):1785-1791, 1996

 

2) Hillner BE, et al:American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 (6):1378-1391, 2000

 

P.317 掲載の参考文献

Kris MG, et al:American Society of Clinical Oncology guideline for antiemetics in oncology:update 2006. J Clin Oncol 24:2932-2947,2006

 

P.319 掲載の参考文献

Loblaw DA, et al:Systematic review of the diagnosis and management of malignant extradural spinal cord compression:the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 23 (9):2028-2037, 2005

 

P.320 掲載の参考文献

Wilson LD, et al:Superior vena cava syndrome with malignant causes. N Engl J Med 356:1862-1869, 2007

PubMed

P.321 掲載の参考文献

Stewart AF:Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 352 (4):373-379, 2005, Review. No abstract available.

 

P.322 掲載の参考文献

Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://www.jcog.jp/

 

書評を投稿する